Inhibition of Enhancer of zeste homolog 2 (EZH2) induces natural killer cell-mediated eradication of hepatocellular carcinoma cells
出版年份 2018 全文链接
标题
Inhibition of Enhancer of zeste homolog 2 (EZH2) induces natural killer cell-mediated eradication of hepatocellular carcinoma cells
作者
关键词
-
出版物
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 115, Issue 15, Pages E3509-E3518
出版商
Proceedings of the National Academy of Sciences
发表日期
2018-03-27
DOI
10.1073/pnas.1802691115
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hepatocellular carcinoma
- (2016) Josep M. Llovet et al. Nature Reviews Disease Primers
- Innate Immune Recognition of Cancer
- (2015) Seng-Ryong Woo et al. Annual Review of Immunology
- Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
- (2015) Katherine B. Chiappinelli et al. CELL
- Regulation of DNA methylation dictates Cd4 expression during the development of helper and cytotoxic T cell lineages
- (2015) MacLean Sellars et al. NATURE IMMUNOLOGY
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ezh2 regulates differentiation and function of natural killer cells through histone methyltransferase activity
- (2015) Jie Yin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A Novel Method for Assessment of Natural Killer Cell Cytotoxicity Using Image Cytometry
- (2015) Srinivas S. Somanchi et al. PLoS One
- MICA/B expression is inhibited by unfolded protein response and associated with poor prognosis in human hepatocellular carcinoma
- (2014) Liang Fang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Regulation of Ligands for the NKG2D Activating Receptor
- (2013) David H. Raulet et al. Annual Review of Immunology
- Oncogenic RAS directs silencing of tumor suppressor genes through ordered recruitment of transcriptional repressors
- (2013) N. Wajapeyee et al. GENES & DEVELOPMENT
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Reduced NKG2D ligand expression in hepatocellular carcinoma correlates with early recurrence
- (2011) Hiroteru Kamimura et al. JOURNAL OF HEPATOLOGY
- Epigenetic effects of polymorphic Y chromosomes modulate chromatin components, immune response, and sexual conflict
- (2010) B. Lemos et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo
- (2009) Tadepally Lakshmikanth et al. JOURNAL OF CLINICAL INVESTIGATION
- NKG2D-Deficient Mice Are Defective in Tumor Surveillance in Models of Spontaneous Malignancy
- (2008) Nadia Guerra et al. IMMUNITY
- The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma
- (2008) Motoko Sasaki et al. LABORATORY INVESTIGATION
- Functions of natural killer cells
- (2008) Eric Vivier et al. NATURE IMMUNOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started